XML 35 R26.htm IDEA: XBRL DOCUMENT
v3.26.1

Fair Value Measurements (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2026
Fair Value Disclosures [Abstract] |
Schedule of fair value liabilities measured on a recurring basis | The following table presents the Company’s financial liabilities that are measured at fair value on a recurring basis and the level of inputs used in such measurements (in thousands):
|  | March 31, 2026 |
|  | Balance |  |  | Quoted Prices in Active Markets (Level 1) |  |  | Significant Other Observable Inputs (Level 2) |  |  | Significant Unobservable Inputs (Level 3) |
Assets |  |  |  |  |  |  |  |  |  |  |  |
Equity method investment, at fair value |  | $ | 79,098 |  |  | $ | 79,098 |  |  | $ | — |  |  | $ | — |
Marketable securities |  |  | 10 |  |  |  | 10 |  |  |  | — |  |  |  | — |
Datavault warrants |  |  | 420 |  |  |  | — |  |  |  | — |  |  |  | 420 |
Digital assets |  |  | 65,345 |  |  |  | 65,345 |  |  |  | — |  |  |  | — |
Total assets |  | $ | 144,873 |  |  | $ | 144,453 |  |  | $ | — |  |  | $ | 420 |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |
Oramed Note |  | $ | 28,862 |  |  | $ | — |  |  | $ | — |  |  | $ | 28,862 |
Tranche B Notes |  |  | 12,010 |  |  |  | — |  |  |  | — |  |  |  | 12,010 |
Purchased revenue liability |  |  | 8,400 |  |  |  | — |  |  |  | — |  |  |  | 8,400 |
Derivative liabilities |  |  | 25,541 |  |  |  | — |  |  |  | — |  |  |  | 25,541 |
Contingent consideration liability |  |  | 5 |  |  |  | 5 |  |  |  | — |  |  |  | — |
Other long-term liabilities |  |  | 177 |  |  |  | — |  |  |  | — |  |  |  | 177 |
Total liabilities |  | $ | 74,995 |  |  | $ | 5 |  |  | $ | — |  |  | $ | 74,990 |
|  | December 31, 2025 |
|  | Balance |  |  | Quoted Prices in Active Markets (Level 1) |  |  | Significant Other Observable Inputs (Level 2) |  |  | Significant Unobservable Inputs (Level 3) |
Assets |  |  |  |  |  |  |  |  |  |  |  |
Equity method investment, at fair value |  | $ | 159,403 |  |  | $ | 159,403 |  |  | $ | — |  |  | $ | — |
Marketable securities |  |  | 6,026 |  |  |  | 6,026 |  |  |  | — |  |  |  | — |
Digital assets |  |  | 64,711 |  |  |  | 64,711 |  |  |  | — |  |  |  | — |
Total assets |  | $ | 230,140 |  |  | $ | 230,140 |  |  | $ | — |  |  | $ | — |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |
Oramed Note |  | $ | 27,688 |  |  | $ | — |  |  | $ | — |  |  | $ | 27,688 |
Tranche B Notes |  |  | 17,500 |  |  |  | — |  |  |  | — |  |  |  | 17,500 |
Purchased revenue liability |  |  | 8,400 |  |  |  | — |  |  |  | — |  |  |  | 8,400 |
Derivative liabilities |  |  | 50,599 |  |  |  | — |  |  |  | — |  |  |  | 50,599 |
Contingent consideration liability |  |  | 3,013 |  |  |  | 3,013 |  |  |  | — |  |  |  | — |
Other long-term liabilities |  |  | 174 |  |  |  | — |  |  |  | — |  |  |  | 174 |
Total liabilities measured at fair value |  | $ | 107,374 |  |  | $ | 3,013 |  |  | $ | — |  |  | $ | 104,361 |
Schedule of the derivative liabilities measured at fair value using significant unobservable inputs Level 3 | The following table includes a summary of the warrant derivative liabilities measured at fair value during the three months ended March 31, 2026 (in thousands):
|  | Fair Value |
Ending Balance as of December 31, 2025 |  | $ | 50,599 |
Change in fair value measurement of warrant liabilities |  |  | (25,709 | )
Issuance of February 2026 Warrants |  |  | 651 |
Ending Balance as of March 31, 2026 |  | $ | 25,541 |
Schedule of quantitative information regarding Level 3 fair value measurements | A summary of the inputs used in valuing the derivative warrant liabilities as of March 31, 2026 is as follows:
|  | Private Warrants |  |  | February 2024 BDO Firm Warrants |  |  | Deposit Warrant |  |  | October 2024 Noteholder Warrants |  |  | December 2024 RDO Common Warrants (5yr) |  |  | December 2024 RDO Common Warrants (2.5yr) |  |  | Exchange Warrants |  | September 2025 Warrants |  | November 2025 Warrants |  | February 2026 Warrants |
Exercise price |  | $ | 402.50 |  |  | $ | 59.50 |  |  | $ | 1.20 |  |  | $ | 36.40 |  |  | $ | 22.72 |  |  | $ | 22.72 |  |  | $ | 40.00 |  | $ | 20.00 |  | $ | 29.00 |  | $ | 20.00 |
Term, in years |  |  | 1.61 |  |  |  | 2.93 |  |  |  | 3.22 |  |  |  | 3.52 |  |  |  | 3.70 |  |  |  | 1.20 |  |  |  | 3.52 |  |  | 3.70 |  |  | 4.70 |  |  | 3.70 |
Volatility |  |  | 120.0 | % |  |  | 99.0 | % |  |  | 90.0 | % |  |  | 93.0 | % |  |  | 91.0 | % |  |  | 116.0 | % |  |  | 93.0 | % |  | 87.0 | % |  | 84.0 | % |  | 99.0 | %
Risk-free rate |  |  | 3.71 | % |  |  | 3.77 | % |  |  | 3.79 | % |  |  | 3.80 | % |  |  | 3.81 | % |  |  | 3.67 | % |  |  | 3.80 | % |  | 3.81 | % |  | 3.86 | % |  | 3.81 | %
Dividend yield |  |  | 0.0 | % |  |  | 0.0 | % |  |  | 0.0 | % |  |  | 0.0 | % |  |  | 0.0 | % |  |  | 0.0 | % |  |  | 0.0 | % |  | 0.0 | % |  | 0.0 | % |  | 0.0 | %
A summary of the inputs used in valuing the derivative warrant liabilities as of December 31, 2025 is as follows:
|  | Private Warrants |  |  | February 2024 BDO Firm Warrants |  |  | Deposit Warrant |  |  | October 2024 Noteholder Warrants |  |  | December 2024 RDO Common Warrants (5yr) |  |  | December 2024 RDO Common Warrants (2.5yr) |  |  | Exchange Warrants |  | September 2025 Warrants |  | November 2025 Warrants |
Exercise price |  | $ | 402.50 |  |  | $ | 59.50 |  |  | $ | 1.20 |  |  | $ | 36.40 |  |  | $ | 22.72 |  |  | $ | 22.72 |  |  | $ | 40.00 |  | $ | 20.00 |  | $ | 29.00 |
Term, in years |  |  | 1.86 |  |  |  | 3.18 |  |  |  | 3.47 |  |  |  | 3.77 |  |  |  | 3.95 |  |  |  | 1.45 |  |  |  | 3.77 |  |  | 3.95 |  |  | 4.90 |
Volatility |  |  | 98.0 | % |  |  | 81.0 | % |  |  | 76.0 | % |  |  | 79.0 | % |  |  | 78.0 | % |  |  | 93.0 | % |  |  | 79.0 | % |  | 74.0 | % |  | 80.0 | %
Risk-free rate |  |  | 3.44 | % |  |  | 3.53 | % |  |  | 3.56 | % |  |  | 3.59 | % |  |  | 3.60 | % |  |  | 3.45 | % |  |  | 3.59 | % |  | 3.60 | % |  | 3.69 | %
Dividend yield |  |  | 0.0 | % |  |  | 0.0 | % |  |  | 0.0 | % |  |  | 0.0 | % |  |  | 0.0 | % |  |  | 0.0 | % |  |  | 0.0 | % |  | 0.0 | % |  | 0.0 | %

X
- Definition Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20 Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-23 + Details
Name: | us-gaap_FairValueConcentrationOfRiskTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of derivative liabilities at fair value. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4E -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B + Details
Name: | us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration